amlodipine has been researched along with Cardiovascular Stroke in 106 studies
Amlodipine: A long-acting dihydropyridine calcium channel blocker. It is effective in the treatment of ANGINA PECTORIS and HYPERTENSION.
amlodipine : A fully substituted dialkyl 1,4-dihydropyridine-3,5-dicarboxylate derivative, which is used for the treatment of hypertension, chronic stable angina and confirmed or suspected vasospastic angina.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In the four SMILE (Survival of Myocardial Infarction Long-Term Evaluation) studies, early administration of zofenopril in acute myocardial infarction (AMI) showed beneficial effects as compared to placebo and other angiotensin converting enzyme inhibitors (ACEIs)." | 9.27 | Efficacy of zofenopril in combination with amlodipine in patients with acute myocardial infarction: a pooled individual patient data analysis of four randomized, double-blind, controlled, prospective studies. ( Ambrosioni, E; Bacchelli, S; Borghi, C; Degli Esposti, D; Omboni, S; Reggiardo, G, 2018) |
| "The acute hemodynamic effects of 20 mg iv amlodipine were evaluated in a placebo-controlled study in 16 normotensive patients 15 +/- 1 days after an acute myocardial infarction by covariance analysis." | 9.08 | Acute hemodynamic effects of amlodipine 15 days after a myocardial infarction in normotensive patients treated with atenolol. ( Baron, B; Bernaud, C; Hotton, JM; Kahn, JC; Marchand, X; Pathé, M; Rocha, P; Zannier, D, 1997) |
| "The effects of 5 and 10 mg of amlodipine and of placebo were compared in 21 patients with stable angina pectoris and multivessel coronary artery disease." | 9.07 | Amlodipine in patients with stable angina pectoris treated with nitrates and beta-blockers. The influence on exercise tolerance, systolic and diastolic functions of the left ventricle. ( Julínek, J; Meluzín, J; Novák, M; Simek, P; Spinarová, L; Stejfa, M; Toman, J; Zeman, K, 1992) |
| "In the present quantitative overview of outcome trials, we investigated the efficacy of amlodipine or angiotensin receptor blockers in the prevention of stroke and myocardial infarction in patients with hypertension, coronary artery disease, or diabetic nephropathy." | 8.84 | Prevention of stroke and myocardial infarction by amlodipine and Angiotensin receptor blockers: a quantitative overview. ( Franklin, SS; Li, Y; Safar, M; Wang, JG, 2007) |
| "We conducted a subgroup analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) to compare metabolic, cardiovascular, and renal outcomes in individuals assigned to initial hypertension treatment with a thiazide-like diuretic (chlorthalidone), a calcium channel blocker (CCB; amlodipine), or an ACE inhibitor (lisinopril) in nondiabetic individuals with or without metabolic syndrome." | 7.74 | Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent ( Baimbridge, C; Barzilay, J; Basile, J; Black, HR; Dart, RA; Davis, B; Marginean, H; Nwachuku, C; Thadani, U; Whelton, P; Wong, ND; Wright, JT, 2008) |
| "The synergistic protective effect of Nicorandil (K(ATP) channel opener) and Amlodipine (calcium channel blocker) on heart tissue antioxidant defense system and lipid profile were examined on isoproterenol induced myocardial infarction in rats." | 7.72 | Synergistic effect of Nicorandil and Amlodipine on tissue defense system during experimental myocardial infarction in rats. ( Devaki, T; Ebenezar, KK; Sathish, V, 2003) |
| "The synergistic effect of nicorandil (K(ATP) channel opener) and amlodipine (calcium channel blocker) on lysosomal hydrolases in serum and heart was examined by determining the activity of beta-glucuronidase, beta-N-acetyl glucosaminidase, beta-galactosidase, cathepsin-D and acid phosphatase on isoproterenol-induced myocardial infarction in rats." | 7.72 | Synergistic effect of nicorandil and amlodipine on lysosomal hydrolases during experimental myocardial infarction in rats. ( Devaki, T; Ebenezar, KK; Sathish, V, 2003) |
| "The synergistic protective effect of nicorandil (KATP channel opener) and amlodipine (calcium channel blocker) on mitochondrial respiration and mitochondrial lipid contents were examined on isoproterenol-induced myocardial infarction in rats." | 7.72 | Biochemical changes on the cardioprotective effect of nicorandil and amlodipine during experimental myocardial infarction in rats. ( Devaki, T; Ebenezar, KK; Sathish, V, 2003) |
| "Possibilities of secondary prevention of reperfusion syndrome with amlodipine was assessed in 46 patients (39 with class III-IV angina after myocardial infarction and 7 with non ST elevation acute coronary syndrome)." | 7.72 | [Reperfusion syndrome after direct myocardial revascularization on beating heart in patients with ischemic heart disease. Possibilities of prevention with amlodipine]. ( Akhmedov, ShD; Dzhavadova, GK; Kandinskiĭ, ML; Tepliakov, AT; Vesnina, ZhV, 2003) |
| "We sought to determine whether reperfusion and the calcium channel blocker amlodipine or the angiotensin-converting enzyme inhibitor enalapril, during healing over six weeks after myocardial infarction (MI), limit structural vascular remodeling in the noninfarct zone (NIZ)." | 7.71 | Vascular remodeling during healing after myocardial infarction in the dog model: effects of reperfusion, amlodipine and enalapril. ( Idikio, H; Jugdutt, BI; Kumar, D; Menon, V, 2002) |
| "The synergistic effects of nicorandil (KATP-channel opener) and amlodipine (calcium-channel blocker) on heart mitochondrial enzymes and the mitochondrial antioxidant defence system was examined on isoproterenol-induced myocardial infarction in rats." | 7.71 | Synergistic effect of nicorandil and amlodipine on mitochondrial function during isoproterenol-induced myocardial infarction in rats. ( Devaki, T; Ebenezar, KK; Sathish, V; Vimal, V, 2002) |
| "To compare the effects of the calcium channel blocker amlodipine versus the angiotensin-converting enzyme inhibitor enalapril with or without reperfusion on infarct collagen and remodelling during healing after anterior myocardial infarction (MI)." | 7.70 | Opposite effects of amlodipine and enalapril on infarct collagen and remodelling during healing after reperfused myocardial infarction. ( Jugdutt, BI; Musat-Marcu, S, 2000) |
| " Male Wistar rats with ligation-induced myocardial infarction were assigned to placebo or treatment with mibefradil (10 mg/kg/day), verapamil (8 mg/kg/day), or amlodipine (4 mg/kg/day) by oral gavage starting 7 days before the induction of myocardial infarction." | 7.70 | Differential effects of mibefradil, verapamil, and amlodipine on myocardial function and intracellular Ca(2+) handling in rats with chronic myocardial infarction. ( Meissner, A; Min, JY; Sandmann, S; Simon, R; Unger, T, 1999) |
| "On the first day after myocardial infarction, the animals were randomly assigned to amlodipine treatment (n = 8) or untreated groups (MI; n = 9)." | 7.70 | Long acting calcium antagonist amlodipine prevents left ventricular remodeling after myocardial infarction in rats. ( Iwao, H; Kim, S; Omura, T; Shimada, T; Takemoto, Y; Takeuchi, K; Yoshikawa, J; Yoshiyama, M, 1998) |
| "In the four SMILE (Survival of Myocardial Infarction Long-Term Evaluation) studies, early administration of zofenopril in acute myocardial infarction (AMI) showed beneficial effects as compared to placebo and other angiotensin converting enzyme inhibitors (ACEIs)." | 5.27 | Efficacy of zofenopril in combination with amlodipine in patients with acute myocardial infarction: a pooled individual patient data analysis of four randomized, double-blind, controlled, prospective studies. ( Ambrosioni, E; Bacchelli, S; Borghi, C; Degli Esposti, D; Omboni, S; Reggiardo, G, 2018) |
| " We sought to determine whether randomization to lisinopril reduces incident AF or atrial flutter (AFL) compared with chlorthalidone in a large clinical trial cohort with extended post-trial surveillance." | 5.24 | Pharmacologic Prevention of Incident Atrial Fibrillation: Long-Term Results From the ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial). ( Albert, CM; Alonso, A; Davis, BR; Dewland, TA; Haywood, LJ; Marcus, GM; Simpson, LM; Soliman, EZ; Yamal, JM, 2017) |
| "Carotid endarterectomy and medical therapy (aspirin) were shown superior to medical therapy alone for asymptomatic (≥ 60%) carotid stenosis." | 5.20 | Optimal medical treatment versus carotid endarterectomy: the rationale and design of the Aggressive Medical Treatment Evaluation for Asymptomatic Carotid Artery Stenosis (AMTEC) study. ( Boytsov, S; Deev, A; Dupik, N; Kolos, I; Loukianov, M, 2015) |
| " The Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension (ACCOMPLISH) trial showed that the combination of benazepril+amlodipine (B+A) is superior to benazepril+hydrochlorothiazide (B+H) in reducing CV events." | 5.20 | Amlodipine+benazepril is superior to hydrochlorothiazide+benazepril irrespective of baseline pulse pressure: subanalysis of the ACCOMPLISH trial. ( Asp, J; Dahlöf, B; Jamerson, KA; Jia, Y; Kjeldsen, SE; Östergren, J; Skoglund, PH; Svensson, P; Weber, MA; Zappe, DH, 2015) |
| "To compare the cost effectiveness of an amlodipine-based strategy and an atenolol-based strategy in the treatment of hypertension in the UK and Sweden." | 5.13 | Economic evaluation of ASCOT-BPLA: antihypertensive treatment with an amlodipine-based regimen is cost effective compared with an atenolol-based regimen. ( Buxton, M; Dahlöf, B; Jönsson, B; Kahan, T; Lindgren, P; Poulter, NR; Sever, PS; Wedel, H, 2008) |
| "The primary objective of this study was to determine whether combination therapy with valsartan 160 mg plus hydrochlorothiazide (HCTZ) 25 mg OD would be more effective than monotherapy with amlodipine 10 mg OD in reducing systolic blood pressure (SBP) in patients with moderate (stage II) hypertension and > or =1 other cardiovascular risk factor or concomitant condition." | 5.11 | Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study. ( Bönner, G; Heintz, D; Kandra, A; Khder, Y; Malacco, E; Ruilope, LM, 2005) |
| "The Antihypertensive and Lipid-Lowering high-risk hypertensive participants, ages > or = 55 years, designed to determine whether the incidence of fatal and nonfatal coronary heart disease (CHD) and combined cardiovascular events (fatal and nonfatal CHD, revascularization surgery, angina pectoris, congestive heart failure, and stroke) differs between diuretic (chlorthalidone) treatment and three alternative antihypertensive therapies: a calcium channel blocker (amlodipine), an ACE inhibitor (lisinopril), and an alpha-adrenergic blocker (doxazosin)." | 5.09 | Baseline characteristics of the diabetic participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ( Barzilay, JI; Basile, JN; Ciocon, JO; Davis, BR; Goff, DC; Jones, CL; Randall, OS; Sweeney, ME, 2001) |
| "To compare the effect of doxazosin, an alpha-blocker, with chlorthalidone, a diuretic, on incidence of CVD in patients with hypertension as part of a study of 4 types of antihypertensive drugs: chlorthalidone, doxazosin, amlodipine, and lisinopril." | 5.09 | Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. ( , 2000) |
| "The acute hemodynamic effects of 20 mg iv amlodipine were evaluated in a placebo-controlled study in 16 normotensive patients 15 +/- 1 days after an acute myocardial infarction by covariance analysis." | 5.08 | Acute hemodynamic effects of amlodipine 15 days after a myocardial infarction in normotensive patients treated with atenolol. ( Baron, B; Bernaud, C; Hotton, JM; Kahn, JC; Marchand, X; Pathé, M; Rocha, P; Zannier, D, 1997) |
| "The aim of this study was to assess the effects of amlodipine on left ventricular function at rest and on effort, at least 30 days after myocardial infarction." | 5.08 | [Tolerance of amlodipine in left ventricular dysfunction of ischemic origin]. ( Albarède, P; de Vernejoul, P; Etienne, D; Feder, JM; Georges, JL; Metzger, JP; Tabone, X; Vacheron, A, 1996) |
| "Once-daily administration of amlodipine is a highly effective treatment for patients with angina pectoris." | 5.07 | Amlodipine in post-infarction angina. ( Taylor, SH, 1992) |
| "The effects of 5 and 10 mg of amlodipine and of placebo were compared in 21 patients with stable angina pectoris and multivessel coronary artery disease." | 5.07 | Amlodipine in patients with stable angina pectoris treated with nitrates and beta-blockers. The influence on exercise tolerance, systolic and diastolic functions of the left ventricle. ( Julínek, J; Meluzín, J; Novák, M; Simek, P; Spinarová, L; Stejfa, M; Toman, J; Zeman, K, 1992) |
| "The risk of myocardial infarction was significantly decreased with an amlodipine-based regimen compared with a non-CCB-based regimen (odds ratio [OR], 0." | 4.90 | Amlodipine and cardiovascular outcomes in hypertensive patients: meta-analysis comparing amlodipine-based versus other antihypertensive therapy. ( Choi, HM; Ko, SK; Lee, HY; Lee, SA; Park, HJ, 2014) |
| "In the present quantitative overview of outcome trials, we investigated the efficacy of amlodipine or angiotensin receptor blockers in the prevention of stroke and myocardial infarction in patients with hypertension, coronary artery disease, or diabetic nephropathy." | 4.84 | Prevention of stroke and myocardial infarction by amlodipine and Angiotensin receptor blockers: a quantitative overview. ( Franklin, SS; Li, Y; Safar, M; Wang, JG, 2007) |
| " hypertension clinical trial databases for amlodipine (Norvasc) and nifedipine in the gastrointestinal therapeutic system (GITS) formulation (Procardia XL)." | 4.80 | Safety of long-acting dihydropyridine calcium channel blockers in hypertensive patients. ( Kloner, RA; Levenstein, M; Materson, BJ; Vetrovec, GW, 1998) |
| "The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) was a randomized clinical trial on the effects of first-step hypertension therapy with amlodipine, chlorthalidone, or lisinopril on fatal coronary heart disease or nonfatal myocardial infarction (1994-2002)." | 3.96 | The effects of antihypertensive class on gout in older adults: secondary analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. ( Beach, JL; Davis, BR; Ishak, A; Juraschek, SP; Mukamal, KJ; Shmerling, RH; Simpson, LM, 2020) |
| " amlodipine in patients with hypertension and different risks of cardiovascular events, followed for a mean of 4." | 3.88 | Blood pressure variability and risk of cardiovascular events and death in patients with hypertension and different baseline risks. ( Berge, E; Hua, TA; Julius, S; Kjeldsen, SE; Liestøl, K; Mancia, G; Mehlum, MH; Parati, G; Rothwell, PM; Weber, MA, 2018) |
| "The pharmacodynamic analysis end point was clopidogrel on-treatment platelet reactivity (OPR) and the clinical analysis end point was the composite of cardiac death, non-fatal myocardial infarction, ischaemic stroke and stent thrombosis at 12 months post-PCI." | 3.78 | Amlodipine, clopidogrel and CYP3A5 genetic variability: effects on platelet reactivity and clinical outcomes after percutaneous coronary intervention. ( Kang, HJ; Kang, J; Kim, HS; Koo, BK; Lee, HY; Oh, BH; Park, JJ; Park, KW; Park, YB; Yang, HM, 2012) |
| "Although amlodipine, a long-acting L-type calcium channel blocker, reportedly prevents left ventricular remodeling and dysfunction after myocardial infarction, the mechanism responsible is not yet well understood." | 3.74 | Amlodipine inhibits granulation tissue cell apoptosis through reducing calcineurin activity to attenuate postinfarction cardiac remodeling. ( Aoyama, T; Esaki, M; Fujiwara, H; Fujiwara, T; Kanamori, H; Kawasaki, M; Maruyama, R; Minatoguchi, S; Miyata, S; Nakagawa, M; Ogino, A; Okada, H; Takemura, G; Ushikoshi, H, 2007) |
| "We conducted a subgroup analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) to compare metabolic, cardiovascular, and renal outcomes in individuals assigned to initial hypertension treatment with a thiazide-like diuretic (chlorthalidone), a calcium channel blocker (CCB; amlodipine), or an ACE inhibitor (lisinopril) in nondiabetic individuals with or without metabolic syndrome." | 3.74 | Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent ( Baimbridge, C; Barzilay, J; Basile, J; Black, HR; Dart, RA; Davis, B; Marginean, H; Nwachuku, C; Thadani, U; Whelton, P; Wong, ND; Wright, JT, 2008) |
| "To examine the association between hospitalization for acute coronary syndromes and treatment with amlodipine or extended-release nifedipine in patients 65 years of age and older." | 3.74 | Dihydropyridine calcium channel blockers and cardiovascular outcomes in elderly patients: a population-based study. ( Bucci, C; Juurlink, DN; Mamdani, MM; Tu, JV, 2008) |
| "Although short-acting nifedipine does not prevent myocardial infarction (MI), calcium antagonists with a long half-life may be effective." | 3.73 | Calcium antagonists for secondary prevention of myocardial infarction: is there a need to shift from short-acting to long-acting types? ( Hayashi, T; Hirano, Y; Ishikawa, K; Kimura, A; Miyataka, M; Taniguchi, M; Taniwa, T, 2005) |
| "Verapamil and amlodipine produced a potent antiischemic effect and reduced the area of myocardial infarction in rats." | 3.72 | Oxygen-dependent mechanisms underlying the antiischemic effect of verapamil and amlodipine. ( Gatsura, SV, 2004) |
| "Possibilities of secondary prevention of reperfusion syndrome with amlodipine was assessed in 46 patients (39 with class III-IV angina after myocardial infarction and 7 with non ST elevation acute coronary syndrome)." | 3.72 | [Reperfusion syndrome after direct myocardial revascularization on beating heart in patients with ischemic heart disease. Possibilities of prevention with amlodipine]. ( Akhmedov, ShD; Dzhavadova, GK; Kandinskiĭ, ML; Tepliakov, AT; Vesnina, ZhV, 2003) |
| "The synergistic protective effect of nicorandil (KATP channel opener) and amlodipine (calcium channel blocker) on mitochondrial respiration and mitochondrial lipid contents were examined on isoproterenol-induced myocardial infarction in rats." | 3.72 | Biochemical changes on the cardioprotective effect of nicorandil and amlodipine during experimental myocardial infarction in rats. ( Devaki, T; Ebenezar, KK; Sathish, V, 2003) |
| "The synergistic effect of nicorandil (K(ATP) channel opener) and amlodipine (calcium channel blocker) on lysosomal hydrolases in serum and heart was examined by determining the activity of beta-glucuronidase, beta-N-acetyl glucosaminidase, beta-galactosidase, cathepsin-D and acid phosphatase on isoproterenol-induced myocardial infarction in rats." | 3.72 | Synergistic effect of nicorandil and amlodipine on lysosomal hydrolases during experimental myocardial infarction in rats. ( Devaki, T; Ebenezar, KK; Sathish, V, 2003) |
| "The synergistic protective effect of Nicorandil (K(ATP) channel opener) and Amlodipine (calcium channel blocker) on heart tissue antioxidant defense system and lipid profile were examined on isoproterenol induced myocardial infarction in rats." | 3.72 | Synergistic effect of Nicorandil and Amlodipine on tissue defense system during experimental myocardial infarction in rats. ( Devaki, T; Ebenezar, KK; Sathish, V, 2003) |
| "The synergistic effects of nicorandil (KATP-channel opener) and amlodipine (calcium-channel blocker) on heart mitochondrial enzymes and the mitochondrial antioxidant defence system was examined on isoproterenol-induced myocardial infarction in rats." | 3.71 | Synergistic effect of nicorandil and amlodipine on mitochondrial function during isoproterenol-induced myocardial infarction in rats. ( Devaki, T; Ebenezar, KK; Sathish, V; Vimal, V, 2002) |
| "We sought to determine whether reperfusion and the calcium channel blocker amlodipine or the angiotensin-converting enzyme inhibitor enalapril, during healing over six weeks after myocardial infarction (MI), limit structural vascular remodeling in the noninfarct zone (NIZ)." | 3.71 | Vascular remodeling during healing after myocardial infarction in the dog model: effects of reperfusion, amlodipine and enalapril. ( Idikio, H; Jugdutt, BI; Kumar, D; Menon, V, 2002) |
| "We measured detailed left ventricular remodeling parameters in vivo (echocardiograms) repeatedly over 6 weeks and ex vivo (planimetry) at 6 weeks after myocardial infarction in 36 dogs randomized (factorial design) after reperfused or nonreperfused myocardial infarction to 6 weeks of twice daily oral therapy with the calcium channel blocker amlodipine (5 mg), the angiotensin-converting enzyme inhibitor enalapril (5 mg) or placebo, and 18 matching sham or control animals." | 3.71 | Beneficial effects of therapy on the progression of structural remodeling during healing after reperfused and nonreperfused myocardial infarction: different effects on different parameters. ( Jugdutt, BI; Menon, V, 2002) |
| "On the first day after myocardial infarction, the animals were randomly assigned to amlodipine treatment (n = 8) or untreated groups (MI; n = 9)." | 3.70 | Long acting calcium antagonist amlodipine prevents left ventricular remodeling after myocardial infarction in rats. ( Iwao, H; Kim, S; Omura, T; Shimada, T; Takemoto, Y; Takeuchi, K; Yoshikawa, J; Yoshiyama, M, 1998) |
| "Calcium channel blockers were widely prescribed at hospital discharge to elderly patients with myocardial infarction between 1994 and 1995 (n = 51,921), the most commonly prescribed being diltiazem (n = 21,175), nifedipine (n = 12,670), amlodipine (n = 11,683), and verapamil (n = 3639)." | 3.70 | Calcium channel blockers and mortality in elderly patients with myocardial infarction. ( Cascio, WE; Chowdhury, MK; Crouse, JR; Jollis, JG; Massing, MW; Simpson, RJ; Smith, SC, 1999) |
| "To compare the effects of the calcium channel blocker amlodipine versus the angiotensin-converting enzyme inhibitor enalapril with or without reperfusion on infarct collagen and remodelling during healing after anterior myocardial infarction (MI)." | 3.70 | Opposite effects of amlodipine and enalapril on infarct collagen and remodelling during healing after reperfused myocardial infarction. ( Jugdutt, BI; Musat-Marcu, S, 2000) |
| " Male Wistar rats with ligation-induced myocardial infarction were assigned to placebo or treatment with mibefradil (10 mg/kg/day), verapamil (8 mg/kg/day), or amlodipine (4 mg/kg/day) by oral gavage starting 7 days before the induction of myocardial infarction." | 3.70 | Differential effects of mibefradil, verapamil, and amlodipine on myocardial function and intracellular Ca(2+) handling in rats with chronic myocardial infarction. ( Meissner, A; Min, JY; Sandmann, S; Simon, R; Unger, T, 1999) |
| "To compare the effects of the calcium channel blocker amlodipine with those of the angiotensin-converting enzyme (ACE) inhibitor enalapril on left ventricular (LV) remodelling and dysfunction during healing after reperfused anterior myocardial infarction (MI)." | 3.69 | Effects of amlodipine versus enalapril on left ventricular remodelling after reperfused anterior myocardial canine infarction. ( Jugdutt, BI, 1997) |
| "2 years in the VALUE trial (Valsartan Antihypertensive Long-Term Use Evaluation)." | 2.94 | Blood Pressure-Lowering Profiles and Clinical Effects of Angiotensin Receptor Blockers Versus Calcium Channel Blockers. ( Berge, E; Julius, S; Kjeldsen, SE; Liestøl, K; Mancia, G; Mehlum, MH; Parati, G; Rothwell, PM; Weber, MA; Wyller, TB, 2020) |
| " We aimed to investigate whether baseline predictors of cardiac morbidity, the major constituent of the primary endpoint in the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial, were different in patients with diabetes and new-onset diabetes compared to patients without diabetes." | 2.82 | Predictors of cardiac morbidity in diabetic, new-onset diabetic and non-diabetic high-risk hypertensive patients: The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial. ( Aksnes, TA; Holzhauer, B; Hua, TA; Julius, S; Kjeldsen, SE; Rostrup, M, 2016) |
| " In the prospective Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial, patients were randomized to valsartan or amlodipine regimens and followed for 4." | 2.82 | No evidence for a J-shaped curve in treated hypertensive patients with increased cardiovascular risk: The VALUE trial. ( Bangalore, S; Berge, E; Holzhauer, B; Hua, TA; Julius, S; Kjeldsen, SE; Mancia, G; Messerli, FH; Weber, MA; Zanchetti, A; Zappe, D, 2016) |
| "The primary composite outcomes were sudden cardiac death, acute myocardial infarction, stroke, coronary revascularization, or hospitalization for heart failure." | 2.78 | Effects of valsartan versus amlodipine in diabetic hypertensive patients with or without previous cardiovascular disease. ( Kondo, T; Maeda, K; Matsushita, K; Muramatsu, T; Murohara, T; Nagahiro, T; Shintani, S; Yamashita, K, 2013) |
| "We conducted retrospective analyses of the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) data." | 2.77 | Cardiovascular outcomes in hypertensive patients: comparing single-agent therapy with combination therapy. ( Brunner, HR; Hua, TA; Jia, Y; Julius, S; Kjeldsen, SE; Mancia, G; McInnes, GT; Schork, A; Weber, MA; Zanchetti, A; Zappe, DH, 2012) |
| "Hypokalemia was associated with increased mortality; however, the statistically significant heterogeneity in hazard ratios across treatment groups strongly suggests that the observed increase in mortality is unrelated to the specific effects of C." | 2.77 | Clinical significance of incident hypokalemia and hyperkalemia in treated hypertensive patients in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. ( Alderman, MH; Calhoun, DA; Cushman, WC; Davis, BR; Eckfeldt, JH; Einhorn, PT; Ford, CE; Franklin, SS; Furberg, CD; Ong, ST; Oparil, S; Papademetriou, V; Piller, LB; Probstfield, JL, 2012) |
| "The occurrence of sudden cardiac death (SCD) in patients with silent ischemia after myocardial infarction (MI) and the factors facilitating SCD are unknown." | 2.74 | Sudden cardiac death in patients with silent myocardial ischemia after myocardial infarction (from the Swiss Interventional Study on Silent Ischemia Type II [SWISSI II]). ( Abbate, A; Erne, P; Jamshidi, P; Kobza, R; Pfisterer, M; Schoenenberger, AW; Stuck, AE; Zuber, M, 2009) |
| "Hypertension is a major cause of heart failure (HF) and is antecedent in 91% of cases." | 2.72 | Role of diuretics in the prevention of heart failure: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. ( Colon, P; Crow, R; Cutler, JA; Davis, BR; Dunn, K; Ellsworth, A; Franklin, S; Furberg, C; Goff, D; Golden, J; Leenen, F; Mohiuddin, S; Papademetriou, V; Piller, LB; Proschan, M, 2006) |
| "amlodipine was associated with lower BPV than other CCBs for both hypertensive patients and hypertensive patients with comorbidity." | 1.48 | Comparison of amlodipine versus other calcium channel blockers on blood pressure variability in hypertensive patients in China: a retrospective propensity score-matched analysis. ( Dong, P; Li, L; Lin, Y; Liu, D; Xie, X; Yang, J; Zhang, L, 2018) |
| "Telmisartan is an angiotensin II receptor blocker, which acts as a partial agonist of peroxisome proliferator activator receptor-γ (PPAR-γ)." | 1.38 | Different roles of PPAR-γ activity on physiological and pathological alteration after myocardial ischemia. ( Hirata, Y; Hishikari, K; Isobe, M; Masumura, M; Nagai, R; Nagashima, A; Ogawa, M; Shimizu, T; Suzuki, J; Takayama, K; Watanabe, R, 2012) |
| "Amlodipine treatment effectively reversed the infarct size augmentation in cholesterol-fed rabbits (46." | 1.30 | Reduction in infarct size by chronic amlodipine treatment in cholesterol-fed rabbits. ( Hori, M; Hoshida, S; Kuzuya, T; Yamashita, N, 1998) |
| "Mibefradil is a calcium antagonist with few negative inotropic effects at therapeutic concentrations." | 1.30 | Unique cardioprotective action of the new calcium antagonist mibefradil. ( Backenköhler, U; Dörge, H; Heusch, G; Jalowy, A; Post, H; Schulz, R; Vahlhaus, C, 1999) |
| "Amlodipine is a dihydropyridine derivative belonging to the group of pharmacologic calcium entry blocking agents and is characterized as having a slow onset and relatively long duration of action with minimal effects on cardiac electrophysiology and myocardial contractility." | 1.28 | Cardioprotective effects of amlodipine in the ischemic-reperfused heart. ( Hoff, PT; Lucchesi, BR; Tamura, Y, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (1.89) | 18.7374 |
| 1990's | 18 (16.98) | 18.2507 |
| 2000's | 47 (44.34) | 29.6817 |
| 2010's | 31 (29.25) | 24.3611 |
| 2020's | 8 (7.55) | 2.80 |
| Authors | Studies |
|---|---|
| Itoga, NK | 1 |
| Tawfik, DS | 1 |
| Montez-Rath, ME | 1 |
| Chang, TI | 1 |
| Du, XL | 1 |
| Simpson, LM | 6 |
| Tandy, BC | 1 |
| Bettencourt, JL | 1 |
| Davis, BR | 19 |
| Lee, HW | 1 |
| Huang, CC | 1 |
| Leu, HB | 1 |
| Lin, YJ | 1 |
| Juraschek, SP | 1 |
| Shmerling, RH | 1 |
| Beach, JL | 1 |
| Ishak, A | 1 |
| Mukamal, KJ | 1 |
| Naseratun, N | 1 |
| Kobara, M | 1 |
| Watanabe, Y | 1 |
| Toba, H | 1 |
| Nakata, T | 1 |
| Mehlum, MH | 2 |
| Liestøl, K | 2 |
| Kjeldsen, SE | 7 |
| Wyller, TB | 1 |
| Julius, S | 5 |
| Rothwell, PM | 2 |
| Mancia, G | 4 |
| Parati, G | 2 |
| Weber, MA | 7 |
| Berge, E | 3 |
| Khayyat-Kholghi, M | 1 |
| Oparil, S | 6 |
| Tereshchenko, LG | 1 |
| Ostroumova, OD | 1 |
| Kochetkov, AI | 1 |
| Arablincky, NA | 1 |
| Shatalova, NA | 1 |
| Romanovsky, RR | 1 |
| Kirichenko, AA | 1 |
| Dewland, TA | 1 |
| Soliman, EZ | 3 |
| Yamal, JM | 2 |
| Alonso, A | 1 |
| Albert, CM | 1 |
| Haywood, LJ | 5 |
| Marcus, GM | 1 |
| Hua, TA | 4 |
| Zhang, L | 1 |
| Yang, J | 1 |
| Li, L | 1 |
| Liu, D | 1 |
| Xie, X | 1 |
| Dong, P | 1 |
| Lin, Y | 1 |
| Borghi, C | 1 |
| Omboni, S | 1 |
| Reggiardo, G | 1 |
| Bacchelli, S | 1 |
| Degli Esposti, D | 1 |
| Ambrosioni, E | 1 |
| Piller, LB | 5 |
| Ghosh, A | 2 |
| Einhorn, PT | 5 |
| Ford, CE | 9 |
| Probstfield, JL | 5 |
| Wright, JT | 5 |
| Kolos, I | 1 |
| Loukianov, M | 1 |
| Dupik, N | 1 |
| Boytsov, S | 1 |
| Deev, A | 1 |
| Cushman, WC | 6 |
| Furberg, CD | 5 |
| Habib, GB | 1 |
| Margolis, K | 1 |
| Whelton, PK | 4 |
| Yamashita, K | 1 |
| Kondo, T | 1 |
| Muramatsu, T | 1 |
| Matsushita, K | 1 |
| Nagahiro, T | 1 |
| Maeda, K | 1 |
| Shintani, S | 1 |
| Murohara, T | 1 |
| Phillips, W | 1 |
| Williamson, JD | 2 |
| Whittle, J | 2 |
| Jafri, SZ | 2 |
| Grimm, RH | 4 |
| Alderman, MH | 4 |
| Park, CG | 1 |
| Lee, SA | 1 |
| Choi, HM | 1 |
| Park, HJ | 1 |
| Ko, SK | 1 |
| Lee, HY | 2 |
| Skoglund, PH | 1 |
| Svensson, P | 1 |
| Asp, J | 1 |
| Dahlöf, B | 4 |
| Jamerson, KA | 1 |
| Jia, Y | 2 |
| Zappe, DH | 2 |
| Östergren, J | 2 |
| Bangalore, S | 1 |
| Messerli, FH | 2 |
| Holzhauer, B | 2 |
| Zappe, D | 1 |
| Zanchetti, A | 2 |
| Aksnes, TA | 1 |
| Rostrup, M | 1 |
| Wald, NJ | 1 |
| Luteijn, JM | 1 |
| Morris, JK | 1 |
| Taylor, D | 1 |
| Oppenheimer, P | 1 |
| Beard, BL | 1 |
| Marginean, H | 2 |
| Hamilton, BP | 1 |
| Suhan, PS | 1 |
| Ernst, ME | 1 |
| Prineas, RJ | 1 |
| Okin, PM | 1 |
| Gao, XM | 1 |
| Tsai, A | 1 |
| Al-Sharea, A | 1 |
| Su, Y | 1 |
| Moore, S | 1 |
| Han, LP | 1 |
| Kiriazis, H | 1 |
| Dart, AM | 1 |
| Murphy, AJ | 1 |
| Du, XJ | 1 |
| Bucci, C | 1 |
| Mamdani, MM | 1 |
| Juurlink, DN | 1 |
| Tu, JV | 1 |
| Little, WC | 1 |
| Kostis, JB | 1 |
| Black, HR | 3 |
| Farber, MA | 1 |
| Levy, D | 1 |
| Massie, BM | 1 |
| Nawaz, S | 1 |
| Schoenenberger, AW | 2 |
| Kobza, R | 1 |
| Jamshidi, P | 1 |
| Zuber, M | 2 |
| Abbate, A | 1 |
| Stuck, AE | 1 |
| Pfisterer, M | 2 |
| Erne, P | 2 |
| Chapman, RH | 1 |
| Yeaw, J | 1 |
| Roberts, CS | 1 |
| Holtkamp, FA | 1 |
| de Zeeuw, D | 1 |
| de Graeff, PA | 1 |
| Laverman, GD | 1 |
| Berl, T | 1 |
| Remuzzi, G | 1 |
| Packham, D | 1 |
| Lewis, JB | 1 |
| Parving, HH | 1 |
| Lambers Heerspink, HJ | 1 |
| Takano, H | 1 |
| Hasegawa, H | 1 |
| Narumi, H | 1 |
| Shindo, S | 1 |
| Mizuma, H | 1 |
| Kuwabara, Y | 1 |
| Kobayashi, Y | 1 |
| Komuro, I | 1 |
| Lynch, AI | 1 |
| Eckfeldt, JH | 2 |
| Boerwinkle, E | 1 |
| Leiendecker-Foster, C | 1 |
| Arnett, DK | 1 |
| Franklin, SS | 3 |
| Papademetriou, V | 2 |
| Ong, ST | 2 |
| Calhoun, DA | 1 |
| Rahman, M | 1 |
| Cutler, JA | 5 |
| Barzilay, JI | 3 |
| Brown, CD | 1 |
| Colon, PJ | 1 |
| Fine, LJ | 1 |
| Gupta, AK | 1 |
| Baimbridge, C | 2 |
| Henriquez, MA | 1 |
| Ilamaythi, E | 1 |
| Preston, R | 1 |
| Nagashima, A | 1 |
| Watanabe, R | 1 |
| Ogawa, M | 1 |
| Suzuki, J | 1 |
| Masumura, M | 1 |
| Hishikari, K | 1 |
| Shimizu, T | 1 |
| Takayama, K | 1 |
| Hirata, Y | 1 |
| Nagai, R | 1 |
| Isobe, M | 1 |
| Whaley-Connell, A | 1 |
| Sowers, JR | 1 |
| Park, KW | 1 |
| Kang, J | 1 |
| Park, JJ | 1 |
| Yang, HM | 1 |
| Kang, HJ | 1 |
| Koo, BK | 1 |
| Oh, BH | 1 |
| Park, YB | 1 |
| Kim, HS | 1 |
| Proschan, M | 2 |
| Graumlich, JF | 1 |
| Pavlik, V | 1 |
| Gordon, D | 1 |
| Blumenthal, SS | 1 |
| Castaldo, RS | 1 |
| Preston, RA | 1 |
| Brunner, HR | 1 |
| McInnes, GT | 2 |
| Schork, A | 1 |
| Düsing, R | 2 |
| Traynor, K | 1 |
| Sathish, V | 4 |
| Ebenezar, KK | 4 |
| Devaki, T | 4 |
| Scott, I | 1 |
| Stowasser, M | 1 |
| Tepliakov, AT | 2 |
| Dzhavadova, GK | 1 |
| Akhmedov, ShD | 1 |
| Kandinskiĭ, ML | 1 |
| Vesnina, ZhV | 1 |
| Rahn, KH | 2 |
| Gatsura, SV | 1 |
| Leenen, FH | 2 |
| Ito, A | 1 |
| Fukumoto, Y | 1 |
| Shimokawa, H | 1 |
| Zidek, W | 1 |
| Verma, S | 1 |
| Strauss, M | 1 |
| Ruilope, LM | 1 |
| Malacco, E | 1 |
| Khder, Y | 1 |
| Kandra, A | 1 |
| Bönner, G | 1 |
| Heintz, D | 1 |
| Taniwa, T | 1 |
| Miyataka, M | 1 |
| Kimura, A | 1 |
| Taniguchi, M | 1 |
| Hirano, Y | 1 |
| Hayashi, T | 1 |
| Ishikawa, K | 1 |
| Lucchesi, BR | 3 |
| Hoff, PT | 2 |
| Tamura, Y | 3 |
| Füessl, HS | 1 |
| Furberg, C | 1 |
| Dunn, K | 1 |
| Franklin, S | 1 |
| Goff, D | 1 |
| Leenen, F | 1 |
| Mohiuddin, S | 1 |
| Ellsworth, A | 2 |
| Golden, J | 1 |
| Colon, P | 1 |
| Crow, R | 1 |
| Nwachuku, CE | 1 |
| Atlas, SA | 1 |
| Basile, JN | 2 |
| Cuyjet, AB | 1 |
| Dart, R | 1 |
| Felicetta, JV | 1 |
| Proschan, MA | 1 |
| Thadani, U | 2 |
| Okura, T | 1 |
| Higaki, J | 1 |
| Pressel, SL | 2 |
| Basile, J | 2 |
| Margolis, KL | 1 |
| Sadler, LS | 1 |
| Summerson, J | 1 |
| Bakris, GL | 1 |
| Pitt, B | 1 |
| Velazquez, E | 1 |
| Gupte, J | 1 |
| Lefkowitz, M | 1 |
| Hester, A | 1 |
| Shi, V | 1 |
| Weir, M | 1 |
| Kjeldsen, S | 1 |
| Massie, B | 1 |
| Nesbitt, S | 1 |
| Ofili, E | 1 |
| Jamerson, K | 1 |
| Wang, JG | 1 |
| Li, Y | 1 |
| Safar, M | 1 |
| Burckhardt, D | 1 |
| Kiowski, W | 1 |
| Dubach, P | 1 |
| Resink, T | 1 |
| Ogino, A | 1 |
| Takemura, G | 1 |
| Kanamori, H | 1 |
| Okada, H | 1 |
| Maruyama, R | 1 |
| Miyata, S | 1 |
| Esaki, M | 1 |
| Nakagawa, M | 1 |
| Aoyama, T | 1 |
| Ushikoshi, H | 1 |
| Kawasaki, M | 1 |
| Minatoguchi, S | 1 |
| Fujiwara, T | 1 |
| Fujiwara, H | 1 |
| Balligand, JL | 1 |
| Godfraind, T | 1 |
| Lindgren, P | 1 |
| Buxton, M | 1 |
| Kahan, T | 1 |
| Poulter, NR | 2 |
| Sever, PS | 2 |
| Wedel, H | 2 |
| Jönsson, B | 1 |
| Davis, B | 1 |
| Barzilay, J | 1 |
| Nwachuku, C | 2 |
| Wong, ND | 1 |
| Whelton, P | 1 |
| Dart, RA | 1 |
| Heidenreich, PA | 1 |
| Lairson, DR | 1 |
| Shlipak, MG | 1 |
| Goldman, L | 1 |
| Feder, JM | 1 |
| Metzger, JP | 1 |
| Georges, JL | 1 |
| Tabone, X | 1 |
| Etienne, D | 1 |
| Albarède, P | 1 |
| de Vernejoul, P | 1 |
| Vacheron, A | 1 |
| Lewis, BS | 1 |
| Rocha, P | 1 |
| Pathé, M | 1 |
| Bernaud, C | 1 |
| Zannier, D | 1 |
| Baron, B | 1 |
| Marchand, X | 1 |
| Hotton, JM | 1 |
| Kahn, JC | 1 |
| Jugdutt, BI | 4 |
| de Vries, RJ | 1 |
| Anthonio, R | 1 |
| van Veldhuisen, DJ | 1 |
| Scholtens, E | 1 |
| Buikema, H | 1 |
| van Gilst, WH | 1 |
| Kloner, RA | 3 |
| Vetrovec, GW | 1 |
| Materson, BJ | 1 |
| Levenstein, M | 1 |
| Fujita, M | 1 |
| Tanaka, T | 1 |
| Nakae, I | 1 |
| Tamaki, S | 1 |
| Kihara, Y | 1 |
| Nohara, R | 1 |
| Sasayama, S | 1 |
| Shimada, T | 1 |
| Yoshiyama, M | 1 |
| Takeuchi, K | 1 |
| Omura, T | 1 |
| Takemoto, Y | 1 |
| Kim, S | 1 |
| Iwao, H | 1 |
| Yoshikawa, J | 1 |
| Hoshida, S | 1 |
| Yamashita, N | 1 |
| Kuzuya, T | 1 |
| Hori, M | 1 |
| Schulz, R | 1 |
| Post, H | 1 |
| Jalowy, A | 1 |
| Backenköhler, U | 1 |
| Dörge, H | 1 |
| Vahlhaus, C | 1 |
| Heusch, G | 1 |
| Fink, KS | 1 |
| Jollis, JG | 1 |
| Simpson, RJ | 1 |
| Chowdhury, MK | 1 |
| Cascio, WE | 1 |
| Crouse, JR | 1 |
| Massing, MW | 1 |
| Smith, SC | 1 |
| Min, JY | 1 |
| Sandmann, S | 2 |
| Meissner, A | 1 |
| Unger, T | 2 |
| Simon, R | 1 |
| Musat-Marcu, S | 1 |
| Jeong, MH | 1 |
| Park, JC | 2 |
| Rhew, JY | 1 |
| Kang, KT | 1 |
| Lee, SH | 1 |
| Cho, JH | 1 |
| Kim, NH | 1 |
| Kim, KH | 1 |
| Ahn, YK | 1 |
| Bae, Y | 1 |
| Cho, JG | 1 |
| Kim, SH | 1 |
| Kang, JC | 1 |
| Schillaci, G | 1 |
| Verdecchia, P | 1 |
| Claas, R | 1 |
| Cleutjens, JP | 1 |
| Daemen, MJ | 1 |
| Vita, JA | 1 |
| Yeung, AC | 1 |
| Winniford, M | 1 |
| Jones, CL | 1 |
| Goff, DC | 1 |
| Ciocon, JO | 1 |
| Sweeney, ME | 1 |
| Randall, OS | 1 |
| Beevers, G | 1 |
| Caulfield, M | 1 |
| Collins, R | 1 |
| Mehlsen, J | 1 |
| Nieminen, M | 1 |
| O'Brien, E | 1 |
| Vimal, V | 1 |
| Bichan, NA | 1 |
| Menon, V | 2 |
| Kumar, D | 1 |
| Idikio, H | 1 |
| Hale, SL | 1 |
| Alker, KJ | 1 |
| Meluzín, J | 1 |
| Stejfa, M | 1 |
| Novák, M | 1 |
| Zeman, K | 1 |
| Spinarová, L | 1 |
| Julínek, J | 1 |
| Toman, J | 1 |
| Simek, P | 1 |
| Hagar, JM | 1 |
| Newman, LG | 1 |
| Taylor, SH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT00000542] | Phase 3 | 0 participants | Interventional | 1993-08-31 | Completed | ||
| Carotid Endarterectomy Versus Optimal Medical Treatment of Asymptomatic High Grade Carotid Artery Stenosis[NCT00805311] | Phase 4 | 400 participants (Actual) | Interventional | 2009-04-30 | Terminated (stopped due to Due to the clear advantage of carotid endarterectomy) | ||
| The Novel Antihypertensive Goal Of hYpertension With diAbetes - Hypertensive Events and ARb Treatment (NAGOYA-HEART) Study[NCT00129233] | Phase 4 | 1,150 participants (Actual) | Interventional | 2004-10-31 | Completed | ||
| Effect of Combined Antihypertensive Therapy on Blood Pressure and Sexual Function in Patients With Essential Hypertension[NCT01238705] | Phase 4 | 280 participants (Anticipated) | Interventional | 2008-04-30 | Recruiting | ||
| DiME Study: Comparison of Diltiazem and Metoprolol in the Management of Acute Atrial Fibrillation or Atrial Flutter With Rapid Ventricular Response: A Prospective Randomized and Double-Blinded Non-Inferiority Trial of Safety and Efficacy[NCT01914926] | Phase 4 | 54 participants (Actual) | Interventional | 2009-06-30 | Completed | ||
| Improving Hypertension Control in Individuals With Diabetes[NCT00743808] | 11,510 participants (Actual) | Observational | 2006-12-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Percent of patient who reached a HR<100bpm within 30 minutes from baseline. (NCT01914926)
Timeframe: 30 minutes
| Intervention | percentage of participants (Number) |
|---|---|
| Metoprolol Study Group | 46.4 |
| Diltiazem Study Group | 95.8 |
7 reviews available for amlodipine and Cardiovascular Stroke
| Article | Year |
|---|---|
Amlodipine and cardiovascular outcomes in hypertensive patients: meta-analysis comparing amlodipine-based versus other antihypertensive therapy.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Chi-Square Distributi | 2014 |
Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin Receptor Antagonists; Biphenyl Compounds; Blood Pressure; | 2011 |
[Recent intervention studies with antihypertensive drugs and their influence on guidelines].
Topics: Adrenergic beta-Antagonists; Aged; Amlodipine; Angiotensin Receptor Antagonists; Angiotensin-Convert | 2003 |
[VALUE].
Topics: Aged; Aged, 80 and over; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agent | 2006 |
Prevention of stroke and myocardial infarction by amlodipine and Angiotensin receptor blockers: a quantitative overview.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Coronary Artery | 2007 |
Calcium antagonists in patients with left ventricular dysfunction: back on the bridge?
Topics: Amlodipine; Calcium Channel Blockers; Felodipine; Humans; Myocardial Infarction; Ventricular Dysfunc | 1996 |
Safety of long-acting dihydropyridine calcium channel blockers in hypertensive patients.
Topics: Amlodipine; Calcium Channel Blockers; Cause of Death; Cerebrovascular Disorders; Clinical Trials as | 1998 |
37 trials available for amlodipine and Cardiovascular Stroke
| Article | Year |
|---|---|
Risk of hospitalized and non-hospitalized gastrointestinal bleeding in ALLHAT trial participants receiving diuretic, ACE-inhibitor, or calcium-channel blocker.
Topics: Aged; Aged, 80 and over; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agen | 2021 |
Blood Pressure-Lowering Profiles and Clinical Effects of Angiotensin Receptor Blockers Versus Calcium Channel Blockers.
Topics: Amlodipine; Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Blood Pre | 2020 |
Pharmacologic Prevention of Incident Atrial Fibrillation: Long-Term Results From the ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial).
Topics: Amlodipine; Antihypertensive Agents; Atrial Fibrillation; Atrial Flutter; Chlorthalidone; Double-Bli | 2017 |
Efficacy of zofenopril in combination with amlodipine in patients with acute myocardial infarction: a pooled individual patient data analysis of four randomized, double-blind, controlled, prospective studies.
Topics: Aged; Amlodipine; Antihypertensive Agents; Captopril; Data Analysis; Double-Blind Method; Female; Ho | 2018 |
Risk Factors Influencing Outcomes of Atrial Fibrillation in ALLHAT.
Topics: Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Atrial Fibrillation; Atrial Flutter; C | 2018 |
Optimal medical treatment versus carotid endarterectomy: the rationale and design of the Aggressive Medical Treatment Evaluation for Asymptomatic Carotid Artery Stenosis (AMTEC) study.
Topics: Amlodipine; Antihypertensive Agents; Aspirin; Carotid Stenosis; Combined Modality Therapy; Endartere | 2015 |
Mortality and morbidity during and after Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: results by sex.
Topics: Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Calcium Channel Blockers; Chlorthalido | 2013 |
Effects of valsartan versus amlodipine in diabetic hypertensive patients with or without previous cardiovascular disease.
Topics: Aged; Amlodipine; Antihypertensive Agents; Cardiovascular Diseases; Case-Control Studies; Death, Sud | 2013 |
Risk of hospitalized gastrointestinal bleeding in persons randomized to diuretic, ACE-inhibitor, or calcium-channel blocker in ALLHAT.
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel | 2013 |
Amlodipine+benazepril is superior to hydrochlorothiazide+benazepril irrespective of baseline pulse pressure: subanalysis of the ACCOMPLISH trial.
Topics: Aged; Amlodipine; Antihypertensive Agents; Benzazepines; Blood Pressure; Double-Blind Method; Drug T | 2015 |
No evidence for a J-shaped curve in treated hypertensive patients with increased cardiovascular risk: The VALUE trial.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Determination; Coronary Ar | 2016 |
Predictors of cardiac morbidity in diabetic, new-onset diabetic and non-diabetic high-risk hypertensive patients: The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Diabetes Complications; Female; Heart Failure; | 2016 |
Clinical and demographic correlates of medication and visit adherence in a large randomized controlled trial.
Topics: Aged; Amlodipine; Antihypertensive Agents; Appointments and Schedules; Black People; Chlorthalidone; | 2016 |
Electrocardiographic measures of left ventricular hypertrophy in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
Topics: Aged; Amlodipine; Antihypertensive Agents; Chlorthalidone; Electrocardiography; Female; Humans; Hype | 2016 |
Heart failure with preserved and reduced left ventricular ejection fraction in the antihypertensive and lipid-lowering treatment to prevent heart attack trial.
Topics: Adrenergic alpha-Antagonists; Aged; Amlodipine; Antihypertensive Agents; Coronary Disease; Double-Bl | 2008 |
Sudden cardiac death in patients with silent myocardial ischemia after myocardial infarction (from the Swiss Interventional Study on Silent Ischemia Type II [SWISSI II]).
Topics: Adrenergic beta-Antagonists; Adult; Aged; Amlodipine; Angioplasty, Balloon, Coronary; Antihypertensi | 2009 |
Effects of valsartan and amlodipine on home blood pressure and cardiovascular events in Japanese hypertensive patients: a subanalysis of the VART.
Topics: Aged; Albuminuria; Amlodipine; Angina Pectoris; Antihypertensive Agents; Asian People; Blood Pressur | 2012 |
Gene panels to help identify subgroups at high and low risk of coronary heart disease among those randomized to antihypertensive treatment: the GenHAT study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Chlorthalidone; Coronary Disease; Doxazosin; Female; Foll | 2012 |
Clinical significance of incident hypokalemia and hyperkalemia in treated hypertensive patients in the antihypertensive and lipid-lowering treatment to prevent heart attack trial.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Chemical Analysis; Cardiovascular Diseases; Chlorth | 2012 |
Long-term renal and cardiovascular outcomes in Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) participants by baseline estimated GFR.
Topics: Amlodipine; Antihypertensive Agents; Canada; Chlorthalidone; Chronic Disease; Coronary Disease; Doub | 2012 |
Cardiovascular outcomes in hypertensive patients: comparing single-agent therapy with combination therapy.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Double-Blind Met | 2012 |
Are thiazide diuretics preferred as first-line therapy for hypertension? An appraisal of The Antihypertensive and Lipid-lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Aged; Amlodipine; Benzothiadiazines; Blood Chemical Analysis; Chlorthalidone; Diuretics; Dose-Respon | 2003 |
Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
Topics: Age Factors; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Cerebrovascular Disorders; D | 2005 |
Role of diuretics in the prevention of heart failure: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
Topics: Adrenergic beta-Antagonists; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihyperte | 2006 |
Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial.
Topics: Amlodipine; Angioedema; Angiotensin-Converting Enzyme Inhibitors; Black People; Blood Glucose; Blood | 2006 |
Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHA
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Glucose; | 2006 |
Baseline characteristics in the Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: a hypertensive population at high cardiovascular risk.
Topics: Aged; Amlodipine; Antihypertensive Agents; Benzazepines; Body Mass Index; Diabetes Mellitus, Type 2; | 2007 |
Effects of anti-ischaemic drug therapy in silent myocardial ischaemia type I: the Swiss Interventional Study on Silent Ischaemia type I (SWISSI I): a randomized, controlled pilot study.
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Adult; Aged; Amlodipine; Bisoprolol; Death, Su | 2007 |
Economic evaluation of ASCOT-BPLA: antihypertensive treatment with an amlodipine-based regimen is cost effective compared with an atenolol-based regimen.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Atenolol; Cost-Benefit Analysis; Diabetes Mellitus | 2008 |
Cost-effectiveness of chlorthalidone, amlodipine, and lisinopril as first-step treatment for patients with hypertension: an analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Chlorthalidone; Cost | 2008 |
[Tolerance of amlodipine in left ventricular dysfunction of ischemic origin].
Topics: Adult; Aged; Amlodipine; Calcium Channel Blockers; Exercise Test; Female; Follow-Up Studies; Hemodyn | 1996 |
Acute hemodynamic effects of amlodipine 15 days after a myocardial infarction in normotensive patients treated with atenolol.
Topics: Acute Disease; Adrenergic beta-Antagonists; Amlodipine; Antihypertensive Agents; Atenolol; Female; H | 1997 |
Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group.
Topics: Adrenergic alpha-Antagonists; Aged; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; C | 2000 |
Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group.
Topics: Adrenergic alpha-Antagonists; Aged; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; C | 2000 |
Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group.
Topics: Adrenergic alpha-Antagonists; Aged; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; C | 2000 |
Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group.
Topics: Adrenergic alpha-Antagonists; Aged; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; C | 2000 |
Baseline characteristics of the diabetic participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Ant | 2001 |
[Effectiveness and safety of amlodipine in secondary prevention in patients with myocardial infarction].
Topics: Adult; Amlodipine; Calcium Channel Blockers; Female; Humans; Male; Middle Aged; Myocardial Infarctio | 2002 |
Amlodipine in patients with stable angina pectoris treated with nitrates and beta-blockers. The influence on exercise tolerance, systolic and diastolic functions of the left ventricle.
Topics: Amlodipine; Angina Pectoris; Diastole; Dose-Response Relationship, Drug; Drug Administration Schedul | 1992 |
Amlodipine in post-infarction angina.
Topics: Amlodipine; Angina Pectoris; Calcium Channel Blockers; Circadian Rhythm; Female; Humans; Male; Middl | 1992 |
62 other studies available for amlodipine and Cardiovascular Stroke
| Article | Year |
|---|---|
Contributions of Systolic and Diastolic Blood Pressures to Cardiovascular Outcomes in the ALLHAT Study.
Topics: Aged; Amlodipine; Blood Pressure; Blood Pressure Determination; Cardiovascular Diseases; Chlorthalid | 2021 |
Comparative efficacy of generic nifedipine versus brand-name amlodipine for hypertension management in Taiwan.
Topics: Amlodipine; Calcium Channel Blockers; Drugs, Generic; Heart Failure; Humans; Hypertension; Ischemic | 2022 |
The effects of antihypertensive class on gout in older adults: secondary analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
Topics: Aged; Amlodipine; Antihypertensive Agents; Atenolol; Blood Pressure; Chlorthalidone; Female; Gout; H | 2020 |
Comparison of effects of L/N-type and L-type calcium channel blockers on post-infarct cardiac remodelling in spontaneously hypertensive rats.
Topics: Amlodipine; Animals; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Calcium Chan | 2020 |
Worsening Kidney Function Is the Major Mechanism of Heart Failure in Hypertension: The ALLHAT Study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Double-Blind Method; Female; Heart Failure; Humans; Hyper | 2021 |
[What do we Mean by "Ideal" Blood Pressure Control?]
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Drug Combinations; Heart Failure; Humans; Hyper | 2021 |
Blood pressure variability and risk of cardiovascular events and death in patients with hypertension and different baseline risks.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Female; Heart Failure; Humans; Hypertensi | 2018 |
Comparison of amlodipine versus other calcium channel blockers on blood pressure variability in hypertensive patients in China: a retrospective propensity score-matched analysis.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; China; Cohort S | 2018 |
Is amlodipine more cardioprotective than other antihypertensive drug classes?
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Heart Failure; Humans | 2014 |
Cost-benefit analysis of the polypill in the primary prevention of myocardial infarction and stroke.
Topics: Aged; Aged, 80 and over; Amlodipine; Aspirin; Cardiovascular Agents; Case-Control Studies; Cohort St | 2016 |
Inhibition of the Renin-Angiotensin System Post Myocardial Infarction Prevents Inflammation-Associated Acute Cardiac Rupture.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Anima | 2017 |
Dihydropyridine calcium channel blockers and cardiovascular outcomes in elderly patients: a population-based study.
Topics: Acute Coronary Syndrome; Aged; Amlodipine; Angina Pectoris; Calcium Channel Blockers; Canada; Cohort | 2008 |
Hypertension, heart failure, and ejection fraction.
Topics: Amlodipine; Calcium Channel Blockers; Heart Failure; Humans; Hypertension; Hypolipidemic Agents; Myo | 2008 |
Association between adherence to calcium-channel blocker and statin medications and likelihood of cardiovascular events among US managed care enrollees.
Topics: Amlodipine; Angina Pectoris; Atorvastatin; Calcium Channel Blockers; Cardiovascular Diseases; Cohort | 2010 |
What your blood pressure isn't revealing.
Topics: Adrenergic beta-Antagonists; American Heart Association; Amlodipine; Anti-Arrhythmia Agents; Antihyp | 2010 |
[Antihypertensive therapy in routine practice: fixed or free combination? Fixed combination scores with better prognosis].
Topics: Amlodipine; Amlodipine, Valsartan Drug Combination; Antihypertensive Agents; Drug Combinations; Huma | 2011 |
Different roles of PPAR-γ activity on physiological and pathological alteration after myocardial ischemia.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Anilides; Animals; Antihypertensive Agents; Ben | 2012 |
Initial choice of antihypertensive on long-term cardiovascular outcomes in CKD.
Topics: Amlodipine; Antihypertensive Agents; Chlorthalidone; Female; Glomerular Filtration Rate; Humans; Hyp | 2012 |
Amlodipine, clopidogrel and CYP3A5 genetic variability: effects on platelet reactivity and clinical outcomes after percutaneous coronary intervention.
Topics: Aged; Amlodipine; Angioplasty, Balloon, Coronary; Clopidogrel; Cytochrome P-450 CYP3A; Drug Interact | 2012 |
How much effect of different antihypertensive medications on cardiovascular outcomes is attributable to their effects on blood pressure?
Topics: Amlodipine; Antihypertensive Agents; Biostatistics; Blood Pressure; Cardiovascular Diseases; Chlorth | 2013 |
[Old or new antihypertensive drugs? Consequences from ALLHAT. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial].
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel | 2003 |
ALLHAT finds diuretics best for initial hypertension therapy.
Topics: Amlodipine; Antihypertensive Agents; Chlorthalidone; Clinical Trials as Topic; Diuretics; Humans; Hy | 2003 |
Synergistic effect of Nicorandil and Amlodipine on tissue defense system during experimental myocardial infarction in rats.
Topics: Amlodipine; Animals; Antihypertensive Agents; Antioxidants; Cholesterol; Drug Synergism; Fatty Acids | 2003 |
ALLHAT--all hit or all miss? Key questions still remain.
Topics: Amlodipine; Antihypertensive Agents; Black People; Chlorthalidone; Humans; Hypolipidemic Agents; Lis | 2003 |
[The new (old) knowledge in primary prevention of stroke. It depends on lowering of blood pressure].
Topics: Adrenergic alpha-Antagonists; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2003 |
Synergistic effect of nicorandil and amlodipine on lysosomal hydrolases during experimental myocardial infarction in rats.
Topics: Administration, Oral; Amlodipine; Animals; Disease Models, Animal; Drug Synergism; Drug Therapy, Com | 2003 |
Biochemical changes on the cardioprotective effect of nicorandil and amlodipine during experimental myocardial infarction in rats.
Topics: Adenosine Diphosphate; Adenosine Triphosphate; Amlodipine; Animals; Cardiovascular Agents; Drug Syne | 2003 |
[Reperfusion syndrome after direct myocardial revascularization on beating heart in patients with ischemic heart disease. Possibilities of prevention with amlodipine].
Topics: Adult; Aged; Amlodipine; Angina Pectoris; Calcium Channel Blockers; Echocardiography, Doppler; Elect | 2003 |
Oxygen-dependent mechanisms underlying the antiischemic effect of verapamil and amlodipine.
Topics: Amlodipine; Animals; Hemoglobins; Lipid Peroxidation; Malondialdehyde; Myocardial Infarction; Myocar | 2004 |
ALLHAT: what has it taught us so far?
Topics: Amlodipine; Antihypertensive Agents; Chlorthalidone; Humans; Hypertension; Lisinopril; Myocardial In | 2004 |
Changing characteristics of patients with vasospastic angina in the era of new calcium channel blockers.
Topics: Administration, Sublingual; Adult; Aged; Aged, 80 and over; Amlodipine; Angina Pectoris, Variant; Ca | 2004 |
[Preventing end-organ damage in hypertension. What is the significance of the VALUE Study for general practice?].
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Calcium Channel Blockers; Cardiovascular Diseas | 2004 |
Angiotensin receptor blockers and myocardial infarction.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphen | 2004 |
Calcium antagonists for secondary prevention of myocardial infarction: is there a need to shift from short-acting to long-acting types?
Topics: Amlodipine; Calcium; Calcium Channel Blockers; Female; Humans; Male; Middle Aged; Myocardial Infarct | 2005 |
Cardioprotective effects of amlodipine in animal models of ischemia and reperfusion.
Topics: Amlodipine; Animals; Blood Pressure; Calcium Channel Blockers; Cardiotonic Agents; Cats; Coronary Ci | 1991 |
[Antihypertensive therapy: campaign of the giants].
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Atenolol; Bendroflumethiazide; Coronary Disease; D | 2005 |
Amlodipine inhibits granulation tissue cell apoptosis through reducing calcineurin activity to attenuate postinfarction cardiac remodeling.
Topics: Amlodipine; Animals; Apoptosis; bcl-Associated Death Protein; Calcineurin; Calcineurin Inhibitors; C | 2007 |
[Treating essential hypertension. Are beta blockers still first choice?].
Topics: Adrenergic beta-Antagonists; Amlodipine; Antihypertensive Agents; Atenolol; Bendroflumethiazide; Cor | 2007 |
Amlodipine and stroke prevention.
Topics: Amlodipine; Blood Pressure; Calcium Channel Blockers; Circadian Rhythm; Humans; Hypertension; Myocar | 2007 |
Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent
Topics: Aged; Amlodipine; Antihypertensive Agents; Atherosclerosis; Blood Pressure; Chlorthalidone; Cohort S | 2008 |
Effects of amlodipine versus enalapril on left ventricular remodelling after reperfused anterior myocardial canine infarction.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Animals; Calcium Channel Blockers; Disease Mod | 1997 |
Effects of amlodipine on endothelial function in rats with chronic heart failure after experimental myocardial infarction.
Topics: Amlodipine; Animals; Blood Pressure; Calcium Channel Blockers; Coronary Disease; Disease Models, Ani | 1997 |
Importance of alpha 1-sympathetic activity for diurnal change in ischemic threshold in patients with stable angina.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Amlodipine; Analysis of Variance; Angina Pectoris; Calciu | 1998 |
Long acting calcium antagonist amlodipine prevents left ventricular remodeling after myocardial infarction in rats.
Topics: Actins; Amlodipine; Animals; Atrial Natriuretic Factor; Blotting, Northern; Calcium Channel Blockers | 1998 |
Reduction in infarct size by chronic amlodipine treatment in cholesterol-fed rabbits.
Topics: Amlodipine; Animals; Aorta; Calcium; Calcium Channel Blockers; Cholesterol, Dietary; Endothelium, Va | 1998 |
Unique cardioprotective action of the new calcium antagonist mibefradil.
Topics: Amlodipine; Animals; Benzimidazoles; Calcium Channel Blockers; Glyburide; Heart; Heart Rate; Heart V | 1999 |
Antihypertensive treatment and CHD in the elderly.
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; | 1999 |
Calcium channel blockers and mortality in elderly patients with myocardial infarction.
Topics: Aged; Aged, 80 and over; Amlodipine; Bepridil; Calcium Channel Blockers; Diltiazem; Female; Humans; | 1999 |
Differential effects of mibefradil, verapamil, and amlodipine on myocardial function and intracellular Ca(2+) handling in rats with chronic myocardial infarction.
Topics: Adrenergic beta-Agonists; Aequorin; Amlodipine; Animals; Calcium; Calcium Channel Blockers; Chronic | 1999 |
Opposite effects of amlodipine and enalapril on infarct collagen and remodelling during healing after reperfused myocardial infarction.
Topics: Amlodipine; Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; Animals; Calcium Channel | 2000 |
Successful management of intractable coronary spasm with a coronary stent.
Topics: Adult; Amlodipine; Aspirin; Calcium Channel Blockers; Cardiovascular Agents; Coronary Angiography; C | 2000 |
[Are all antihypertensive agents equal? Cardiovascular events in hypertensive patients randomized to treatment with doxazosin or chlorthalidone. The ALLHAT study].
Topics: Adrenergic alpha-Antagonists; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2000 |
Calcium channel blockade limits cardiac remodeling and improves cardiac function in myocardial infarction-induced heart failure in rats.
Topics: Amlodipine; Animals; Calcium Channel Blockers; Heart Failure; Hemodynamics; Hypertrophy, Left Ventri | 2001 |
Coronary artery reactivity after treatment with simvastatin.
Topics: Amlodipine; Bezafibrate; Coronary Angiography; Coronary Artery Disease; Coronary Disease; Coronary V | 2001 |
Anglo-Scandinavian Cardiac Outcomes Trial: a brief history, rationale and outline protocol.
Topics: Amlodipine; Antihypertensive Agents; Atenolol; Benzothiadiazines; Coronary Disease; Diuretics; Human | 2001 |
Synergistic effect of nicorandil and amlodipine on mitochondrial function during isoproterenol-induced myocardial infarction in rats.
Topics: Amlodipine; Animals; Calcium Channel Blockers; Creatine Kinase; Drug Synergism; Isoproterenol; L-Lac | 2002 |
Vascular remodeling during healing after myocardial infarction in the dog model: effects of reperfusion, amlodipine and enalapril.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Animals; Biomarkers; Calcium Channel Blockers; | 2002 |
Beneficial effects of therapy on the progression of structural remodeling during healing after reperfused and nonreperfused myocardial infarction: different effects on different parameters.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Animals; Calcium Channel Blockers; Cardiac Vol | 2002 |
Absence of hemodynamic deterioration in the presence of amlodipine following experimental myocardial infarction.
Topics: Amlodipine; Animals; Coronary Circulation; Disease Models, Animal; Dogs; Electrocardiography; Female | 1992 |
Effects of amlodipine on myocardial infarction, infarct expansion, and ventricular geometry in the rat.
Topics: Amlodipine; Analysis of Variance; Animals; Calcium Channel Blockers; Female; Heart; Heart Ventricles | 1992 |
Cardioprotective effects of amlodipine in the ischemic-reperfused heart.
Topics: Amlodipine; Animals; Calcium Channel Blockers; Cats; Dogs; Heart; In Vitro Techniques; Myocardial Co | 1989 |
Cardioprotective effects of amlodipine in the ischemic-reperfused heart.
Topics: Amlodipine; Animals; Blood Pressure; Calcium; Calcium Channel Blockers; Cats; Compliance; Coronary C | 1989 |